MIIST 305
Alternative Names: MIIST-305Latest Information Update: 02 May 2024
At a glance
- Originator Synedgen
- Class Anti-inflammatories; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders; Ulcerative colitis
Most Recent Events
- 25 Apr 2024 Preclinical trials in Ulcerative colitis in USA (PO) prior to April 2024
- 25 Apr 2024 Synedgen plans to initiate a phase I trial for Gastrointestinal disorders and Ulcerative colitis
- 25 Apr 2024 Synedgen plans to submit an Investigational New Drug application for MIIST 305 for Gastrointestinal disorders and Ulcerative colitis